Last Updated : March 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Cosentyx | Secukinumab | ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Cosentyx | Secukinumab | Arthritis, psoriatic | Reimburse with clinical criteria and/or conditions | Complete | ||
Jardiance | Empagliflozin | Diabetes mellitus, type 2 with high cardiovascular risk | Reimburse with clinical criteria and/or conditions | Complete | ||
Synjardy | Empagliflozin and metformin | Diabetes mellitus (Type 2) | Reimburse with clinical criteria and/or conditions | Complete | ||
Viacoram | perindopril arginine / amlodipine | Hypertension, essential | Reimburse with clinical criteria and/or conditions | Complete | ||
N/A | bevacizumab and lomustine | Recurrent glioblastoma multiform | Reimburse with clinical criteria and/or conditions | Complete | ||
Paxlovid | nirmatrelvir/ritonavir | Mild-to-moderate COVID-19, treatment | Active | |||
Epidiolex | cannabidiol | Lennox-Gastaut Syndrome (LGS) | Active | |||
Epidiolex | cannabidiol | Dravet Syndrome (DS) | Active | |||
Libtayo | cemiplimab | Locally advanced or metastatic NSCLC (first line) | Active |